Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    Whooping Cough Vaccination Rates Stay the Same Despite Epidemic

    By Global Biodefense StaffMay 5, 2014
    Biodefense Vaccine Development
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    DTAP VaccineConventional wisdom holds that when the risk of catching a disease is high, people are more likely to get vaccinated to protect themselves. This may not be the case, however, according to a study presented today at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

    Researchers, led by Elizabeth R. Wolf, MD, FAAP, compared rates of infant vaccination with the diphtheria, tetanus and pertussis vaccine (DTaP) before and during an epidemic of pertussis (whooping cough) in Washington state. Surprisingly, they found no difference in vaccination rates.

    “We have always assumed that when the risk of catching a disease is high, people will accept a vaccine that is effective in preventing that disease. Our results may challenge this assumption,” said Dr. Wolf, the Ruth L. Kirschstein National Research Service Award Fellow in General Academic Pediatrics at University of Washington, Seattle Children’s Research Institute.

    Washington state experienced a pertussis epidemic from Oct. 1, 2011, through Dec. 31, 2012, and infants were hit the hardest. The highly contagious bacterial disease causes uncontrollable, violent coughing that can make it hard to breathe. Pertussis also is known as whooping cough because a “whooping” sound often is heard when the patient tries to take a breath. Pertussis can lead to pneumonia, seizures (jerking and staring spells), brain damage and death.

    Dr. Wolf and her colleagues compared the proportion of 3- to 8-month-olds who had received the recommended number of doses of pertussis-containing vaccine before the epidemic and during the epidemic. Infants who received at least one dose by 3 months of age, at least two doses by 5 months and at least three doses by 7 months are considered up to date by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.

    “We hypothesized that a whooping cough epidemic would result in more parents getting their children immunized against whooping cough,” Dr. Wolf said. “But compared to a time before the 2011-2012 whooping cough epidemic in Washington state, there was no significant increase in receipt of whooping cough vaccines for infants during the epidemic.”

    Results did show considerable variability in vaccination rates among different counties.

    “Vaccination rates in the U.S. are still below public health goals,” Dr. Wolf noted. “We don’t fully understand what improves vaccine acceptance. This study found no significant increase in vaccination coverage statewide during the 2011-2012 pertussis epidemic. This finding may challenge the assumption that vaccine acceptance uniformly increases when risk of disease is high.”

    The study was funded by a grant from the National Institutes of Health.

    NIH Vaccine News Whooping Cough
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBAA – Multiplex Diagnostic Platforms for Infectious Diseases
    Next Article DARPA Seeks Cutting Edge Biological Technologies

    Related Stories

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.